About
vVARDIS Holding AG
vVARDIS has created a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth.
Our proprietary peptide-enabled technology platform, Curodont®, delivers an early therapeutic solution for tooth decay, the world’s most prevalent non-communicable disease, addressing a massive global healthcare need that has historically lacked effective early-intervention medical treatment options.
Our Curodont® platform includes our flagship Curodont® products—Curodont® Repair Fluoride Plus, which is currently sold in the United States and generates the vast majority of our revenues, and Curodont® Repair, which is currently sold in our other markets.
vVARDIS Holding AG Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| F-1 | Oct 9, 2026 | Registration statement for certain foreign private issuers |
| DRS/A | Sep 15, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Aug 11, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Jul 2, 2026 | [Cover] Draft Registration Statement |
| D | Oct 25, 2022 | Notice of Exempt Offering of Securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Haley Abivardi
Co-Chief Executive Officer, Co-Founder and Co-Chair
Goly Abivardi
Co-Chief Executive Officer, Co-Founder and Co-Chair
Thomas Rondot
Chief Financial Officer and Chief People Officer
Juergen Stark
Director
Clifford zur Nieden
Director
